Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden.

Autor: Andersson E; The Swedish Institute for Health Economics, Råbyvägen 2, 223 61, Lund, Sweden. emelie.andersson@ihe.se., Brådvik G; The Swedish Institute for Health Economics, Råbyvägen 2, 223 61, Lund, Sweden., Nilsson FOL; Pfizer AB, Solnavägen 3H, 113 63, Stockholm, Sweden., Arpegård J; Pfizer AB, Solnavägen 3H, 113 63, Stockholm, Sweden., Strambi A; Pfizer AB, Solnavägen 3H, 113 63, Stockholm, Sweden.; Present address: Fondazione Toscana Life Sciences, Siena, Italy., Kollberg P; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85, Umeå, Sweden., Carlsson KS; The Swedish Institute for Health Economics, Råbyvägen 2, 223 61, Lund, Sweden.; Department of Clinical Sciences, Malmö, Health Economics, Lund University, BMC F12, 221 84, Lund, Sweden.
Jazyk: angličtina
Zdroj: BMC urology [BMC Urol] 2024 Jul 17; Vol. 24 (1), pp. 148. Date of Electronic Publication: 2024 Jul 17.
DOI: 10.1186/s12894-024-01536-2
Abstrakt: Background: Bladder cancer (BC) and Renal cell carcinoma (RCC) are the most common urogenital cancers among both sexes, with a yearly global incidence of around 500 000 each. Both BC and RCC have been linked to diabetes. Poor glycemic control (malglycemia) is a serious consequence of diabetes and a possible consequence of systemic treatments used in BC and RCC. The objective of this study was to investigate the prevalence of diabetes and use of hospital-based care for malglycemia in people with BC or RCC.
Methods: This Swedish retrospective population-based register study used national health-data registers for longitudinal data on cancer incidence covering 15 years, use of hospital-based health care, and filled prescriptions of outpatient medications. Study endpoints included co-prevalence of diabetes in individuals with BC/RCC, healthcare resource utilization due to malglycemia, use of systemic corticosteroids, and changes in diabetes management for people with concomitant type 2 diabetes.
Results: We identified 36,620 and 15,581 individuals diagnosed with BC and RCC, respectively, between 2006 and 2019. The proportion of individuals registered with diabetes was 24% in BC and 23% in RCC. An association between BC/RCC and poor glycemic control was found, although the number of malglycemic events in hospital-based care were few (65/59 per 1000 individuals with diabetes and BC/RCC respectively with at least one event). An earlier switch to insulin-based diabetes management was observed in BC/RCC compared to matched individuals with type 2 diabetes but no cancer. The results also indicated an association between steroid treatment and poor glycemic control, and that systemic corticosteroids were more common among people with BC/RCC compared to diabetes controls.
Conclusion: The high prevalence of diabetes and increased use of systemic corticosteroid treatment observed in this large national study highlights the need for specific clinical management, risk-assessment, and monitoring of individuals with BC/RCC and diabetes.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: